SMShinsuke Miyano

Shinsuke Miyano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shinsuke Miyano has a total of 90 co-authors. Here are the top co-authors by number of shared publications:

  • Kenichi Komada

    Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan

    5 shared publications
  • Masahiko Hachiya

    Bureau of International Health Cooperation, National Center for Global Health and Medicine, Toyama, Shinjuku-ku, Tokyo, Japan

    5 shared publications
  • Yasunori Ichimura

    Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan

    4 shared publications
  • Kenichi Komada

    Bureau of International Health Cooperation and World Health Organization Collaborating Center for Health Systems Development, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan

    3 shared publications
  • Makoto Takeda

    Department of Virology 3 and World Health Organization Global Specialized Laboratory for Measles and Rubella, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan

    3 shared publications
  • Chankham Tengbriacheu

    Minist Hlth, Natl Immunizat Program, Mother & Child Hlth Ctr, Viangchan, Laos

    2 shared publications

Latest Publications

  • Open Access

    Age-specific prevalence of IgG against measles/rubella and the impact of routine and supplementary immunization activities: A multistage random cluster sampling study with mathematical modelling

    by Masahiko Hachiya, Emilia Vynnycky, Yoshio Mori, Hung Thai Do, Mai Kim Huynh, Long Hoang Trinh, Duy Duc Nguyen, Nhu Anh Thi Tran, Thanh Tien Hoang, Hai Hang Thi Hoang, et al.


  • Open Access

    Estimates of the global burden of Congenital Rubella Syndrome, 1996-2019

    by Emilia Vynnycky, Jennifer K. Knapp, Timos Papadopoulos, Felicity T. Cutts, Masahiko Hachiya, Shinsuke Miyano, Susan E. Reef


  • Open Access

    Comparison of population-based measles-rubella immunoglobulin G antibody prevalence between 2014 and 2019 in Lao People's Democratic Republic: Impacts of the national immunization program

    by Shinsuke Miyano, Emilia Vynnycky, Chansay Pattamavone, Yasunori Ichimura, Yoshio Mori, Phonethipsavanh Nouanthong, Kongxay Phounphenghack, Chankham Tengbriacheu, Bouaphne Khamphaphongphane, Lauren Franzel, et al.


  • Open Access

    Prevalence of hepatitis B and C virus infections in Lao People’s Democratic Republic: The first national population-based cross-sectional survey

    by Shinsuke Miyano, Chansay Pathammavong, Yasunori Ichimura, Masaya Sugiyama, Kongxay Phounphenghack, Chankham Tengbriacheu, Bouaphane Khamphaphongphane, Phonethipsavanh Nouanthong, Lauren Franzel, Tae Un Yang, et al.

    Population-based seroprevalence of chronic hepatitis B and C infections has not been examined in Lao People’s Democratic Republic (PDR). Therefore, this study aimed to estimate the seroprevalence of these infections in the general population of Lao PDR and perform subgroup analysis. A nationwide seroprevalence survey was conducted in Lao PDR in June 2019 using the multistage cluster sampling method. Dried blood spot samples were collected onto WhatmanTM 903 filter paper by finger prick. A chemiluminescent microparticle immunoassay was used to measure the levels of hepatitis B surface antigen (HBsAg) and hepatitis C antibody (HCV-Ab). Samples in which the HBsAg level was above 0.05 IU/ml and HCV-Ab was above the signal/cutoff ratio of 1.0 were considered positive based on comparisons with the relative light unit value of a calibration sample. A total of 1,927 samples (male: 47.3%, mean age: 23.0 years) were included in the analysis. The prevalence was estimated to be 4.2% (95% confidence interval [CI]: 2.7–6.3) for HBsAg and 1.6% (95% CI: 0.5–5.3) for HCV-Ab. Multivariable analysis revealed that those aged 20–24 years (adjusted odds ratio (AOR): 2.3, 95% CI: 1.1–4.6), those aged 25–29 years (AOR: 2.7, 95% CI: 1.3–5.6), those from the Northern region (AOR: 2.8, 95% CI: 1.2–6.6), and those who were Khmu (AOR: 3.6, 95% CI: 2.0–6.8) or Hmong (AOR: 5.0, 95% CI: 3.3–7.5) were significantly more likely to be positive for HBsAg. Although there were no statistically significant differences in the HCV-Ab prevalence according to each variable, males (2.9%, 95% CI: 0.7–10.7), those aged ≥40 years (6.1%, 95% CI: 2.1–16.8), and those from the Southern region (3.3%, 95% CI: 0.6–15.3) tended to have a higher prevalence. This novel population-based survey found differences in the prevalence of chronic hepatitis B and hepatitis C virus infections in Lao PDR according to sex, age group, region, and ethnicity; however, the results of this study should be confirmed in future studies, and relevant responses tailored for each target also need to be determined to control the transmission of hepatitis B and C infections.


  • Open Access

    Comparison between a rapid diagnostic test and dried blood spot-based immunoassay for hepatitis B surface antigen testing: Performance and cost implications in a population-based serosurvey in Vietnam

    by Sumiyo Okawa, Kenichi Komada, Yasunori Ichimura, Masaya Sugiyama, Hung Thai Do, Huy Xuan Le, Thanh Tien Hoang, Trieu Bao Nguyen, Mai Kim Huynh, Hang Thi Hai Hoang, et al.


  • Open Access

    Public knowledge, practices, and awareness of antibiotics and antibiotic resistance in Myanmar: The first national mobile phone panel survey

    by Shinsuke Miyano, Thi Thi Htoon, Ikuma Nozaki, Eh Htoo Pe, Htay Htay Tin

    In 2017, the Myanmar National Action Plan for Containment of Antimicrobial Resistance (AMR) (2017–2022) was endorsed by the Ministry of Health and Sports, Myanmar; one of its objectives was to increase public awareness of AMR to accelerate appropriate antibiotic use. This survey aimed to assess the public knowledge, practices and awareness concerning antibiotics and AMR awareness among adults in Myanmar. We conducted a nationwide cross-sectional mobile phone panel survey in January and February 2020. Participants were randomly selected from the mobile phone panel in each of three groups stratified by gender, age group, and residential area urbanity; they were interviewed using a structured questionnaire. Collected data were weighted based on the population of each stratum from the latest national census and analyzed using descriptive and inferential statistics. Two thousand and forty-five adults from 12 regions and states participated in this survey. Overall, 89.5% of participants had heard about antibiotics; however, only 0.9% provided correct answers to all five questions about antibiotics, whereas 9.7% provided all incorrect answers. More than half of participants (58.5%) purchased antibiotics without a prescription, mainly from medical stores or pharmacies (87.9%); this was more frequent in age group (18–29 years) and those in rural areas (p = 0.004 and p < 0.001, respectively). Only 56.3% were aware of antibiotic resistance and received their information from medical professionals (46.3%), family members or friends (38.9%), or the media (26.1%). Less than half (42.4%) knew that antibiotics were used in farm animals. Most did not know that using antibiotics in farm animals could develop resistance (73.2%) and is banned for the purposes of growth stimulation (64.1%). This survey identifies considerable gaps in the knowledge, practices, and awareness about antibiotics among the general population in Myanmar. Continuous public education and awareness campaigns must be urgently conducted to fulfill these gaps, which would aid in promoting antibiotic stewardship, leading to combating AMR in Myanmar.


  • Open Access

    Effectiveness of immunization activities on measles and rubella immunity among individuals in East Sepik, Papua New Guinea: A cross-sectional study

    by Yasunori Ichimura, Masato Yamauchi, Naoko Yoshida, Shinsuke Miyano, Kenichi Komada, Moe Moe Thandar, Steven Tiwara, Toshihiro Mita, Francis W Hombhanje, Yoshio Mori, et al.


  • Open Access

    Seroprevalence of mumps before the introduction of mumps-containing vaccine in Lao PDR: results from a nationwide cross-sectional population-based survey

    by Hironori Okabayashi, Kenichi Komada, Minoru Kidokoro, Tomomi Kitamura, Shinsuke Miyano, Tomoo Ito, Kongxay Phounphenghak, Chansay Pathammavong, Keiko Murano, Misato Nagai, et al.

    Objective: Mumps-containing vaccine is currently not a component of the national immunization schedule in Lao People's Democratic Republic (PDR). Mumps itself is not a notifiable disease in the country and the seroprevalence of anti-mumps immunoglobulin G (IgG) in the general population is unknown. In this study, anti-mumps IgG was measured in 2058 blood samples to evaluate population immunity in the country. Results: The seroprevalence of anti-mumps IgG showed a gradual increase with increasing age, starting at 10.6% (95% CI 7.4-13.7) in participants aged 1-2 years, and almost plateaued at about 75% in individuals older than 11-12 years, though it still tended toward a small increase up to 89.6% (95% CI 86.6-92.6) in participants aged 40 years or older. Compared with the results of previous studies, this increase with increasing age is less marked and the plateau of anti-mumps seroprevalence is lower. We attribute this result mainly to the lower population density in Lao PDR.


  • Open Access

    Cost-effectiveness analysis of the national decentralization policy of antiretroviral treatment programme in Zambia

    by Shinsuke Miyano, Gardner Syakantu, Kenichi Komada, Hiroyoshi Endo, Tomohiko Sugishita

    In resource-limited settings with a high prevalence of human immunodeficiency virus (HIV) infection such as Zambia, decentralization of HIV/acquired immunodeficiency syndrome (HIV/AIDS) treatment and care with effective use of resources is a cornerstone of universal treatment and care. This research aims to analyse the cost effectiveness of the National Mobile Antiretroviral Therapy (ART) Services Programme in Zambia as a means of decentralizing ART services. Cost-effectiveness analyses were performed using a decision analytic model and Markov model to compare the original ART programme, ‘Hospital-based ART’, with the intervention programme, Hospital-based plus ‘Mobile ART’, from the perspective of the district government health office in Zambia. The total cost of ART services, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) were examined. The mean annual per-patient costs were 1259.16 USD for the original programme and 2601.02 USD for the intervention programme, while the mean number of QALYs was 6.81 for the original and 7.27 for the intervention programme. The ICER of the intervention programme relative to the original programme was 2965.17 USD/QALY, which was much below the willingness-to-pay (WTP), or three times the GDP per capita (4224 USD), but still over the GDP per capita (1408 USD). In the sensitivity analysis, the ICER of the intervention programme did not substantially change. The National Mobile ART Services Programme in Zambia could be a cost-effective approach to decentralizing ART services into rural areas in Zambia. This programme could be expanded to more districts where it has not yet been introduced to improve access to ART services and the health of people living with HIV (PLHIV) in rural areas.


  • Open Access

    Longitudinal adherence to antiretroviral drugs for preventing mother-to-child transmission of HIV in Zambia

    by Sumiyo Okawa, Mable Chirwa, Naoko Ishikawa, Henry Kapyata, Charles Yekha Msiska, Gardner Syakantu, Shinsuke Miyano, Kenichi Komada, Masamine Jimba, Junko Yasuoka

    Adherence to antiretroviral (ARV) drugs is essential for eliminating new pediatric infections of human immunodeficiency virus (HIV). Since the Zambian government revised the national guidelines based on option A (i.e., maternal zidovudine and infant ARV prophylaxis) of the World Health Organization’s 2010 guidelines, no studies have assessed adherence to ARVs during pregnancy up to the postpartum period. This study aimed to examine adherence to ARVs and identify the associated risk factors. A prospective cohort study was conducted in the Chongwe district from June 2011 to January 2014. Self-reported adherence to ARVs was examined during pregnancy and at one week, six weeks, and 24 weeks postpartum among 321 HIV-positive women. The probability of remaining adherent to ARVs was estimated using the Kaplan-Meier method, and the risk factors for non-adherence were identified using the Cox proportional hazard regressions—treating loss to follow-up as non-adherence. The statuses of HIV in HIV-exposed infants were assessed in January 2014. During the study period, 326 infants were born to HIV-positive women, 262 (80.4 %) underwent HIV testing, and 11 (3.4 %) had their HIV infection detected at the time that they had the latest HIV testing as of January 2014. The ARV adherence rate was 82.5 % during pregnancy, 84.2 % at one week postpartum, 81.5 % at six weeks postpartum, and 70.5 % at 24 weeks postpartum. The probability of remaining adherent to ARVs was 0.61 at day 50, 0.35 at day 100, 0.18 at day 200, and 0.06 at day 300. Attending a referral health center (HC) was a risk factor for non-adherence compared with attending rural HCs that provided HIV care/treatment (adjusted hazard ratio [aHR] 0.71, 95 % confidence interval [CI] 0.57–0.88) and those that did not provide HIV care/treatment (aHR 0.58, 95 % CI 0.46–0.74). A new diagnosis of HIV infection compared to a known HIV-positive status before pregnancy was another risk factor for non-adherence (aHR 1.24, 95 % CI 1.03–1.50). Maintaining adherence to ARVs through pregnancy to the postpartum period remains a crucial challenge in Zambia. To maximize the treatment benefits, adherence to ARVs and retention in care should be improved at all health facilities.